HIF

FibroGen to Participate at Stifel 2022 Healthcare Conference

Retrieved on: 
Tuesday, November 1, 2022
Pancreatic cancer, Duchenne, MDS, Duchenne muscular dystrophy, IPF, Conference, GLOBE, Idiopathic pulmonary fibrosis, Research, Dialysis, HIF, DMD, Anemia, CTGF, NASDAQ, CIA, Company, CKD, Patient, Biology, SAN, Therapy, LAPC, Microdeletion syndrome, Pharmaceutical industry, Roxadustat

SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY taking place on November 15, at 1:50 PM Eastern Time.

Key Points: 
  • SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY taking place on November 15, at 1:50 PM Eastern Time.
  • A live audio webcast of the event will be available on the Events & Presentations section of the FibroGen Investors webpage at www.fibrogen.com.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.
  • FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space.

FibroGen to Report Third Quarter 2022 Financial Results

Retrieved on: 
Monday, October 24, 2022
SAN, Pancreatic cancer, Interest, Therapy, Webcast, Dialysis, CTGF, IPF, HIF, NASDAQ, Microdeletion syndrome, MDS, Biology, Patient, Research, Duchenne, DMD, Duchenne muscular dystrophy, Anemia, Company, Idiopathic pulmonary fibrosis, GLOBE, CKD, LAPC, CIA, Pharmaceutical industry, Roxadustat

SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close.

Key Points: 
  • SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close.
  • FibroGen will also conduct a conference call on that day at 5:00 p.m.
  • ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
  • FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space.

Emerald Health Pharmaceuticals Reports Data Showing Novel Drug Candidate is First-in-class B55α/PP2A Activator

Retrieved on: 
Thursday, October 13, 2022
Emerald, SAN, News, CA, Cannabidiol, Orphan, MS, Stroke, Hope, Multiple sclerosis, Paper, HIF, Scleroderma, COO, Patient, Research, Traumatic brain injury, EHP, Technology, Company, Doctor of Philosophy, MD, Pharming, Systemic scleroderma, Safety, Degenerative disease, CNS, GLOBE, Forward-looking statement, Journal of Neuroinflammation, FDA, Autoimmunity, Pharmaceutical industry, EU

SAN DIEGO, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (“EHP” or the “Company”), a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases, today announced the publication of a scientific article in the peer-reviewed Journal of Neuroinflammation highlighting additional data supporting the unique mechanism of action of EHP-101, the company’s first-in-class drug candidate for the treatment of systemic sclerosis (SSc) and multiple sclerosis (MS).

Key Points: 
  • This first-in-class activator of the HIF pathway via modulation of B55a provides a new mechanism to treat diseases where vascular integrity is compromised.
  • About Emerald Health Pharmaceuticals Inc.
    Emerald Health Pharmaceuticals is developing novel product candidates for the treatment of CNS, autoimmune, and other diseases.
  • The Companys second product candidate, EHP-102, is in non-clinical development withIND-enabling studiesand is focused on treating Parkinsons disease and Huntingtons disease.
  • Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA

Harbert Infrastructure Fund VI, LP Announces Final Close

Retrieved on: 
Thursday, October 6, 2022
HIF, Harbert Management Corporation, Insurance, Foundation, GLOBE, Income, COO, HMC, Investment, Renewable energy, Financial services

BIRMINGHAM, Ala., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Harbert Infrastructure Fund VI, LP (HIF VI) had its final close on September 30, 2022.

Key Points: 
  • BIRMINGHAM, Ala., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Harbert Infrastructure Fund VI, LP (HIF VI) had its final close on September 30, 2022.
  • Since 1986, Harbert Infrastructure has deployed over $7.6 billion across 56 investments with varied fuel sources, technologies, and transaction structures.
  • HMC President and COO, Travis Pritchett added, We are immensely proud of the latest Harbert Infrastructure close.
  • HIF VI is an investment vehicle of Harbert Management Corporation (HMC) which held its final closing on September 30, 2022.

Hemp Pilot Part of $9.88 million grant in Lake Decatur Water Quality Initiative

Retrieved on: 
Monday, August 22, 2022
Partnership, U.S. Department of Defense Strategy for Operating in Cyberspace, Total addressable market, CEO, Soybean, HIF, Water quality, City, Nitrate, Hemp, Farmer, Water, GLOBE, TAM, Founder CEO, Association, Public policy, Climate change, Environment, NHA, Renewable energy, Agriculture, Aquaculture

We will work alongside the City of Decatur and the Illinois Hemp Growers Association to implement a Climate-Smart hemp pilot program within the larger project.

Key Points: 
  • We will work alongside the City of Decatur and the Illinois Hemp Growers Association to implement a Climate-Smart hemp pilot program within the larger project.
  • "The Illinois Hemp Growers Association is excited to hear that plans for the RCPP Lake Decatur Water Quality Initiative have been approved.
  • We expect to see novel developments on the impact of hemp on water quality as a result of this first of its kind project.
  • Lake Decatur Water Quality Initiatives overall objective is to collaborate with the USDA Natural Resources Conservation Service and 53 partners to help farmers and landowners adopt Climate-Smart practices.

Former Societe Generale Managing Director Roberto Simon joins HIF Global as CFO

Retrieved on: 
Wednesday, August 10, 2022
Multimedia, Carbon, CEO, Forward-looking statement, HIF, Policy, Hydrogen, Review, SG, Société Générale, Simon, Financial services

HOUSTON, Aug. 10, 2022 /PRNewswire/ -- HIF Global, the world's leading eFuels company, announced that Roberto Simon will join the company as its new Chief Financial Officer. Simon previously served as Managing Director and Co-Head of Global Banking and Advisory at Societe Generale (SG) Americas in New York.

Key Points: 
  • Simon previously served as Managing Director and Co-Head of Global Banking and Advisory at Societe Generale (SG) Americas in New York.
  • At HIF he will deliver financial strategy and capital markets expertise to ensure our success.Roberto's leadership within Societe Generale and in global financial markets is unparalleled.
  • During his 25-year career at Societe Generale, Roberto Simon worked with leading companies and sponsors throughout the world to finance pioneering transactions, setting new benchmarks for the sector.
  • HIF Chile, HIF USA, HIF Asia Pacific, and HIF EMEA are wholly owned subsidiaries of HIF Global.

FibroGen Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
MDS, U.S. Securities and Exchange Commission, Chronic kidney disease, Risk, GLOBE, Failure, Pamrevlumab, CTGF, SEC, Investment, NRDL, Security (finance), Research, Annual report, Marketing, Patient, Completeness, Biology, Erythropoiesis, Idiopathic pulmonary fibrosis, Food, Organ dysfunction, HIF, Sale, SAN, Safety, NDD, Orphan, Webcast, Commonwealth, Dialysis, IPF, Duchenne muscular dystrophy, Growth, CIA, Mission statement, JDE, Scar, CKD, Anemia, Erythropoietin, DMD, AstraZeneca, Fast Track, Duchenne, Microdeletion syndrome, ODD, Review, LAPC, Company, Pancreatic cancer, Therapy, NASDAQ, Adult, Animal, Video game, Pharmaceutical industry, Medical device, Aluminium, Medicine, Roxadustat, Astellas Pharma, Roxadustat

2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021

Key Points: 
  • 2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021
    SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2022 and provided an update on the companys recent developments.
  • Second quarter total roxadustat net sales in China1 by FibroGen and the distribution entity (JDE) jointly owned by FibroGen and AstraZeneca was $53.1 million, compared to $52.8 million in the second quarter of 2021.
  • Total revenue for the second quarter of 2022 was $29.8 million, as compared to $24.4 million for the second quarter of 2021.
  • FibroGen will host a conference call and webcast today, Monday, August 8, 2022, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss financial results and provide a business update.

FibroGen to Report Second Quarter 2022 Financial Results

Retrieved on: 
Monday, July 25, 2022
IPF, Duchenne, HIF, GLOBE, CKD, CTGF, DMD, LAPC, SAN, Pancreatic cancer, Research, Interest, Chronic kidney disease, NASDAQ, Webcast, Duchenne muscular dystrophy, Company, Biology, Therapy, Idiopathic pulmonary fibrosis, CIA, Microdeletion syndrome, MDS, Anemia, Pharmaceutical industry

SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close.

Key Points: 
  • SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close.
  • FibroGen will also conduct a conference call on that day at 5:00 p.m.
  • ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
  • FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space.

Huawei Launches the SOCC Solution, Safeguarding Stable Transactions in the Financial Industry

Retrieved on: 
Monday, July 25, 2022
Dorado, SOCC, DCI, Solution, Technology, Huawei, Lists of people executed in the United States, HIF, Renewable energy, Mobile phone

This solution leverages the advantages of storage devices and optical transmission products to prevent financial transaction failures caused by network jitter, ensuring stable and reliable financial transactions.

Key Points: 
  • This solution leverages the advantages of storage devices and optical transmission products to prevent financial transaction failures caused by network jitter, ensuring stable and reliable financial transactions.
  • To reduce the impact of network jitter on financial transactions, Huawei's SOCC solution enables direct handshakes through the SOCC channel between the industry-leading financial DCI optical transmission device OptiXtrans DC908 and all-flash storage OceanStor Dorado.
  • Huawei SOCC solution is designed for the financial industry to solve service loss caused by link switching and ensure the stable financial transactions.
  • Huawei Intelligent Finance Summit (HiFS) is Huawei's annual flagship event for the global financial industry.

FibroGen to Participate at William Blair Biotech Focus Conference 2022

Retrieved on: 
Friday, July 1, 2022
Patient, Duchenne muscular dystrophy, Biology, Research, IPF, Dialysis, Microdeletion syndrome, GLOBE, CTGF, DMD, Company, Pancreatic cancer, SAN, Idiopathic pulmonary fibrosis, Anemia, Therapy, Duchenne, HIF, CKD, MDS, NASDAQ, LAPC, CIA, Conference, Pharmaceutical industry, Roxadustat

SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 taking place the week of July 11, 2022.

Key Points: 
  • SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 taking place the week of July 11, 2022.
  • A webcast of the event will be available Monday, July 11 at 9:00am ET on the Events & Presentations section of the FibroGen Investors webpage at www.fibrogen.com.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.
  • FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space.